Geode Capital Management
TPTX

Geode Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Geode Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-871,686
Closed -$65.6M – 5082
2022
Q2 		$65.6M Sell
871,686
-41,681
-5% -$1.85M 0.01% 931
2022
Q1 		$24.5M Buy
913,367
+11,984
+1% +$403K ﹤0.01% 1758
2021
Q4 		$43M Buy
901,383
+70,983
+9% +$3.17M 0.01% 1420
2021
Q3 		$55.2M Buy
830,400
+45,344
+6% +$3.23M 0.01% 1193
2021
Q2 		$61.3M Buy
785,056
+107,116
+16% +$7.92M 0.01% 1134
2021
Q1 		$64.1M Buy
677,940
+50,758
+8% +$6.04M 0.01% 1031
2020
Q4 		$76.4M Buy
627,182
+89,462
+17% +$9.8M 0.01% 827
2020
Q3 		$47M Buy
537,720
+166,837
+45% +$11.6M 0.01% 950
2020
Q2 		$24M Buy
370,883
+58,515
+19% +$3.38M 0.01% 1373
2020
Q1 		$13.9M Buy
312,368
+41,113
+15% +$2.18M ﹤0.01% 1531
2019
Q4 		$16.9M Buy
271,255
+124,236
+85% +$5.91M ﹤0.01% 1670
2019
Q3 		$5.53M Buy
147,019
+29,563
+25% +$1.29M ﹤0.01% 2324
2019
Q2 		$4.78M Buy
+117,456
New +$4.19M ﹤0.01% 2423

Geode Capital Management's TPTX Position: Q3 2022 in Review

Geode Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 871,686 shares — an estimated $65.6M sold.

Geode Capital Management first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $76.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Geode Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Geode Capital Management sold 871,686 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $65.6M.
  • Geode Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • Geode Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $76.4M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Geode Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.